文献速递白血病淋巴瘤

伊布替尼联合维奈克拉治疗复发/难治性慢性淋巴细胞白血病:CLARITY 研究

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
PubMed 文献 · J Clin Oncol · 2019-07-11

CLARITY 是一项 II 期试验,在复发/难治性慢性淋巴细胞白血病(CLL)患者中联合伊布替尼与维奈克拉,主要终点为联合治疗 12 个月后清除可测残留病灶(MRD)。

要点

  • 联合治疗 12 个月后血液 MRD 阴性率 53%、骨髓 36%,部分患者得以停药。
  • 仅见 1 例生化性肿瘤溶解综合征,其他不良反应轻微和/或可控,最常见为中性粒细胞减少或胃肠道事件。

核心结论

  • 伊布替尼联合维奈克拉在复发/难治性 CLL 患者中耐受性良好,MRD 清除率高并使部分患者停止治疗,无进展生存与总生存结果令人鼓舞。

研究设计与样本

  • CLARITY 是一项 II 期试验,在复发/难治性 CLL 患者中联合伊布替尼与维奈克拉;主要终点为联合治疗 12 个月后 MRD 清除,关键次要终点包括按国际 CLL 工作组标准的缓解、安全性及无进展生存和总生存;共 53 例患者。

主要发现

  • 联合治疗 12 个月后,血液 MRD 阴性(每 10,000 个白细胞中少于 1 个 CLL 细胞)28 例(53%),骨髓 MRD 阴性 19 例(36%)。
  • 中位随访 21.1 个月时 1 例患者进展,全部患者存活。
  • 观察到 1 例生化性肿瘤溶解综合征;其他不良反应轻微和/或可控,最常见为中性粒细胞减少或胃肠道事件。

关键数值与推荐

  • MRD 阴性定义为每 10,000 个白细胞中少于 1 个 CLL 细胞。
  • 主要终点为联合治疗 12 个月后 MRD 清除;关键次要终点为按国际 CLL 工作组标准的缓解、安全性、无进展生存和总生存。

临床怎么用

  • 对复发/难治性 CLL 可采用伊布替尼联合维奈克拉治疗,12 个月后评估 MRD,MRD 清除者部分可停止治疗。
  • 治疗期间需关注肿瘤溶解综合征及中性粒细胞减少、胃肠道事件等不良反应。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both significantly improve survival in CLL and replace chemoimmunotherapy for many patients. However, individually, they rarely lead to eradication of measurable residual disease (MRD) and usually are taken indefinitely or until progression. We present the CLARITY trial that combined ibrutinib with venetoclax to eradicate detectable CLL with the intention of stopping therapy. PATIENTS AND METHODS: CLARITY is a phase II trial that combined ibrutinib with venetoclax in patients with relapsed or refractory CLL. The primary end point was eradication of MRD after 12 months of combined therapy. Key secondary end points were response by International Workshop on CLL criteria, safety, and progression-free and overall survival. RESULTS: In 53 patients after 12 months of ibrutinib plus venetoclax, MRD negativity (fewer than one CLL cell in 10,000 leukocytes) was achieved in the blood of 28 (53%) and the marrow of 19 (36%). Forty-seven patients (89%) responded, and 27 (51%) achieved a complete remission. After a median follow-up of 21.1 months, one patient progressed, and all patients were alive. A single case of biochemical tumor lysis syndrome was observed. Other adverse effects were mild and/or manageable and most commonly were neutropenia or GI events. CONCLUSION: The combination of ibrutinib plus venetoclax was well tolerated in patients with relapsed or refractory CLL. There was a high rate of MRD eradication that led to the cessation of therapy in some patients. The progression-free and overall survival rates are encouraging for relapsed and refractory CLL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. J Clin Oncol. 2019. PMID: 31295041. doi:10.1200/JCO.19.00894

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。